Effect of myocardial dysfunction in cardiac morbidity and all cause mortality in childhood cancer subjects treated with anthracycline therapy

Table 2 The effect of risk factors on development of myocardial dysfunction (SF < 29 %) – Univariate and multiple logistic regression analysis

Risk Factors^{a, b}	Unadjusted OR	95 % CI	p-value	Adjusted OR	95 % CI	p-value
Years post-chemo	0.99	0.96, 1.00	0.87	---	---	---
Age at Diagnosis	1.04	1.00, 1.08	0.04	1.00	0.96, 1.05	0.99
Gender	1.16	0.74, 1.83	0.51	---	---	---
Cumulative dose	3.36	2.06, 5.49	<0.001	3.27	1.94, 5.49	<0.001
Radiation to chest	1.82	0.99, 3.33	0.05	1.50	0.76, 2.96	0.24
Vinca Alkaloids	0.80	0.46, 1.37	0.41	---	---	---
BMT	2.98	1.57, 5.64	0.001	2.57	1.24, 5.30	0.01
Previous heart disease^c	2.09	1.05, 4.15	0.04	1.87	0.85, 4.12	0.12
Cardio-protective drugs	1.86	0.80, 4.32	0.15	---	---	---

^aRisk factors for cardiotoxicity include increased length of post-chemotherapy interval (years), younger age at diagnosis, female gender, total cumulative dose ≥240 mg/m², radiation therapy to the chest, treatment with vinca alkaloids, bone marrow transplant, previous heart disease, non-use of cardio-protective drugs
^bThe 5 significant risk factors upon univariate analysis were selected as covariates for the multiple logistic regression model (younger age at diagnosis, total cumulative dose anthracyclines > 240 mg/m², radiation to the chest, BMT and previous heart disease)
^cPrevious heart disease defined as: presence of congenital heart disease, pericardial effusion/tamponade, SVC syndrome, myocardial dysfunction prior to chemotherapy

ISSN: 2057-3804